Radiation countermeasure agents: an update (2011-2014).

ABSTRACT:

Introduction

Despite significant scientific advances over the past 60 years towards the development of a safe, nontoxic and effective radiation countermeasure for the acute radiation syndrome (ARS), no drug has been approved by the US FDA. A radiation countermeasure to protect the population at large from the effects of lethal radiation exposure remains a significant unmet medical need of the US citizenry and, thus, has been recognized as a high priority area by the government.

Area covered

This article reviews relevant publications and patents for recent developments and progress for potential ARS treatments in the area of radiation countermeasures. Emphasis is placed on the advanced development of existing agents since 2011 and new agents identified as radiation countermea

SUBMITTER: Singh VK 

PROVIDER: S-EPMC4438421 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature